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Objectives: Treatment switching refers to the situation in a randomized controlled trial where patients switch from their randomly assigned treatment onto an alternative. Often,
switching is from the control group onto the experimental treatment. In this instance, a standard intention-to-treat analysis does not identify the true comparative effectiveness of
the treatments under investigation. We aim to describe statistical methods for adjusting for treatment switching in a comprehensible way for nonstatisticians, and to summarize
views on these methods expressed by stakeholders at the 2014 Adelaide International Workshop on Treatment Switching in Clinical Trials.
Methods: We describe three statistical methods used to adjust for treatment switching: marginal structural models, two-stage adjustment, and rank preserving structural failure time
models. We draw upon discussion heard at the Adelaide International Workshop to explore the views of stakeholders on the acceptability of these methods.
Results: Stakeholders noted that adjustment methods are based on assumptions, the validity of which may often be questionable. There was disagreement on the acceptability of
adjustment methods, but consensus that when these are used, they should be justified rigorously. The utility of adjustment methods depends upon the decision being made and the
processes used by the decision-maker.
Conclusions: Treatment switching makes estimating the true comparative effect of a new treatment challenging. However, many decision-makers have reservations with adjustment
methods. These, and how they affect the utility of adjustment methods, require further exploration. Further technical work is required to develop adjustment methods to meet real
world needs, to enhance their acceptability to decision-makers.
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Treatment switching in a randomized controlled trial (RCT)
occurs when patients in one group switch from the treatment
specified for that group to the treatment specified for another
group in the trial (most commonly from the control treatment
to the experimental treatment) or to another treatment that is
not part of the original trial protocol. The situation primarily
arises due to ethical concern for the patient; the Declaration
of Helsinki dictates that the goal of knowledge generation can
never take precedence over the interests of individual research
subjects (1). Therefore, if early analysis, or external informa-
tion, suggests that clinical equipoise between the treatments un-
der investigation is lost, there may be an ethical requirement to
permit switching. The presence of switching in clinical trials
creates difficulties in estimating the true effectiveness and cost-
effectiveness of experimental treatments (2–4). This has impli-
cations for drug manufacturers, regulators, payers, clinicians,
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and future patients: ultimately, a reliance on standard statisti-
cal techniques to analyze RCTs affected by treatment switch-
ing could result in effectiveness and harms being underesti-
mated and access being denied to effective and cost-effective
treatments. The policy issues around treatment switching are
discussed in more depth in the accompanying study (5).
Statistical methods have been developed to adjust for the
confounding introduced by treatment switching. The purpose
of this study is to describe key adjustment methods and their
main assumptions in a way that is understandable to nonstatis-
ticians, and to summarize and discuss the implications of the
views on the acceptability of these methods that were expressed
by stakeholders at the 2014 Adelaide International Workshop
on Treatment Switching in Clinical Trials.
BACKGROUND
The Adelaide workshop provided a platform for the discussion
of the contentious issue of treatment switching. Stakeholder
representatives from around the world were brought together
with a view to identify where there is agreement on appropriate
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approaches to address treatment switching in the design and
analysis of oncology trials, and where further development is
needed. The key stakeholders were identified as patients (and
their representatives), oncologists, ethicists, statisticians, in-
dustry, regulators, health technology assessment (HTA) agen-
cies, and payers. The main issues addressed at the Workshop
included the design and management of oncology RCTs, the
analysis, interpretation and validation of trial results, and their
use in decision making.
The statistical adjustment methods can appear to be a com-
plicated “black-box” to nonstatisticians. The fact that the work-
ings of these methods are not widely understood has inhibited
their acceptability, and therefore, usefulness. It became appar-
ent during the Workshop that the general level of understand-
ing of the adjustment methods needs to be improved, particu-
larly in the HTA and payer communities. This study seeks to
address this issue by explaining the principles of statistical ad-
justment methods and how they work in a way that is accessible
to nonstatisticians. Diagrams are included to provide illustrated
examples, but are presented only in the Supplementary Mate-
rial for this study. We urge readers to refer to these diagrams to
follow the explanations given for the adjustment methods; the
diagrams are an integral part of the study.
ADJUSTING FOR TREATMENT SWITCHING
The Methods
A variety of adjustment methods were discussed at the Work-
shop, including their assumptions, strengths and weaknesses.
This section provides an explanation of the approaches con-
sidered to be the most relevant for the switching observed in
RCTs (2). We do not seek to explain all of the complexities of
the methods; references are given for more detailed discussions
available in the literature.
A standard intention-to-treat (ITT) analysis is generally ac-
cepted as the preferred approach for analyzing RCTs (6). The
ITT analysis compares treatment groups as initially random-
ized, maintaining the balance generated by randomization and
avoiding biases that can arise in intervention research such as
nonrandom attrition of participants from the study (7;8). How-
ever, in the presence of treatment switching, the ITT analysis is
not suited to the task of estimating the magnitude of the relative
effect of the new treatment. If (as is usually the case) patients
switch because they or their clinician believe that the experi-
mental treatment has demonstrated superiority, the ITT analy-
sis would generally be expected to provide an underestimate of
the true effect of the experimental treatment compared with the
control.
One approach to addressing the switching problem is to
simply exclude patients who switch from the analysis, or to
“censor” them from analysis at the point of switch. However,
this approach is highly prone to selection bias, because switch-
ers are likely to be prognostically different from nonswitch-
ers (9–12). There is a general view that this “naïve” approach
should be avoided (2–4).
Various more sophisticated adjustment methods have been
developed to address the challenge of switching. Those cur-
rently considered most valid are (2,11–13): (i) marginal struc-
tural models (MSM) using inverse probability of censoring
weighting (IPCW); (ii) two-stage adjustment; and (iii) rank
preserving structural failure time models (RPSFTM) using g-
estimation. These three approaches are described and discussed
below.
Marginal Structural Models and Inverse Probability of Censoring Weights
It is simplest to think of the MSM with IPCWmethod as an ex-
tension of the simple censoring approach, whereby the bias as-
sociated with censoring is removed through the use of a weight-
ing mechanism and the creation of a “pseudo population” (a
population adjusted for the distortions that arise from the prog-
nostic differences between switchers and nonswitchers) (14).
The MSM with IPCW approach involves three key steps.
(1) First, switchers are censored at the point of switch. In Supplementary Fig-
ure 1a, we illustrate survival times observed for ten patients (five control
group patients, and five experimental group patients) from a fictitious
RCT, in which switching from the control group onto the experimental
treatment was permitted after disease progression. In this example, three
of the five control group patients switched, and are censored at the point
of switch.
(2) Second, baseline and time-dependent information on patient characteris-
tics that are prognostic factors for mortality and that influence the prob-
ability of switching are identified. These might include factors such as
age and/or tumor burden and should be prespecified, and/or based on ev-
idence or expert opinion. A dataset is then created such that each patient
has a full set of values for these prognostic characteristics from random-
ization to the time of last contact. Models are fitted to this dataset to
predict the probability of not switching in control group patients, con-
ditional on the identified prognostic factors (Supplementary Figure 1b).
These probabilities are used to determine the size of the weight applied
to each patient.
Control group patients who did not switch but who have similar patient
characteristics to patients who did switch are assigned higher weights,
allowing them to account for themselves and for similar patients who
switched. The weights may change for each patient over time, as the
characteristics displayed by patients change. In our example, Patient 2, a
control group patient who did not switch treatments, must have displayed
dissimilar prognostic characteristics to patients who switched, because
he or she received weights of less than 1.0 throughout his or her survival
experience. In contrast, Patient 5 must have displayed similar prognostic
characteristics to switchers, because he or she received a weight of greater
than 1.0 after disease progression. All experimental group patients re-
ceive a weight of 1.0 throughout the MSM/IPCW analysis, because we
do not wish to adjust for any switching in the experimental group (in this
example). This step creates the (weighted) pseudo population.
(3) Finally, an analysis to estimate the adjusted treatment effect is under-
taken (typically, a standard Cox regression model [15] is used to es-
timate a hazard ratio) (Supplementary Figure 1c). The Kaplan-Meier
graph of survival probability against time presented in Supplementary
Figure 1c presents the observed control group and experimental group
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Kaplan-Meier curves, and the Kaplan-Meier curve of the weighted con-
trol group (i.e., the pseudo population).
The main challenge in using the MSM/IPCW approach
is to ensure that the weightings compensate appropriately for
the bias created by censoring switchers. For this to be fully
achieved, data must be available at baseline and over time on
all prognostic factors for mortality that also influence switch-
ing; this is known as the assumption of “no unmeasured con-
founding” (14–16). We can never be sure that this assumption
holds, because we do not have perfect knowledge on which
characteristics are prognostic. However, a clear statement of
which prognostic characteristics have been considered and why
(e.g., based upon data from other trials and/or clinical judge-
ment), and comprehensive data collection on these may help
to re-assure decision makers that the result of an MSM/IPCW
analysis is credible.
A further problem is that, although it may be desirable to
include as many potentially prognostic covariates as possible
within the MSM/IPCW analysis, in relatively small RCTs this
may lead to convergence issues, that is, the method does not
produce a result. Also, specific patients may be assigned very
high weights, particularly if there are very few control group
patients who did not switch treatments. In this case, the method
becomes prone to substantial error, because there is a higher
likelihood that these remaining patients may not be representa-
tive of the wider trial population.
Two-Stage Adjustment
The Two-Stage adjustment method to address the treatment
switching problem was developed for the situation that of-
ten pertains in RCTs of oncology treatments, where switching
only occurs after disease progression (2;12;13). The method
involves three steps, which allow survival times that would
have been observed in the absence of switching to be estimated
(these are also known as “counterfactual” survival times).
(1) First, a “secondary baseline” is identified for patients in the control group
(assuming that we wish to adjust for switching only in the control group).
Switching must only occur after this secondary baseline. Supplementary
Figure 2 provides an illustration of a Two-Stage adjustment analysis ap-
plied to the fictitious RCT previously introduced. In this example, the
point of disease progression is used as the secondary baseline for each
patient (Supplementary Figure 2a).
(2) Second, postsecondary baseline (in this case post-disease progression)
survival is analyzed within the control group (Supplementary Figure 2b).
A treatment effect (in the form of an “time ratio”) associated with the
experimental treatment is then estimated specifically for control group
switching patients, compared with control group nonswitchers, using a
model that is adjusted for patient characteristics measured at the time of
the secondary baseline. Patients are assumed to be at a similar stage of
disease at the secondary baseline, and if prognostic characteristics are
measured at this time-point we can adjust for any differences between
switchers and nonswitchers, and thus produce an unbiased estimate of
the treatment effect in switchers. The prognostic characteristics consid-
ered here are similar to those considered in the MSM/IPCW method pre-
viously described, but for the Two-Stage method, data are only required
on these at the time of disease progression, not beyond.
(3) Third, the treatment effect associated with switching is used to “shrink”
the survival times observed in switchers, to provide estimates of the sur-
vival times that would have been observed in the absence of switching
(Supplementary Figure 2c). The adjusted control group survival times
are then compared with observed experimental group survival times to
obtain an estimate of the adjusted treatment effect.
This approach is reliant on switching occurring after a spe-
cific disease-related time-point, so that a secondary baseline
can be defined. At this time-point, the assumption of “no un-
measured confounders” must hold (information must be avail-
able on all patient characteristics that are associated with sur-
vival), creating similar challenges to those discussed for this
assumption in the previous section. A further limitation of the
Two-Stage method is that it only adjusts for differences be-
tween switchers and nonswitchers at the time of the secondary
baseline: it does not capture any changes in patient character-
istics that may occur between the secondary baseline and the
time of switch. Hence, switching must occur soon after the sec-
ondary baseline, otherwise differences between switchers and
nonswitchers may not be adequately adjusted for.
The Two-Stage adjustment method is prone to convergence
issues if trial sample sizes are small, particularly if there are
several important prognostic characteristics. Also, estimates of
the treatment effect in switchers will be prone to error if there
are very few control group patients who do not switch. How-
ever, research has suggested that the Two-Stage adjustment
method is less sensitive to these issues than the MSM/IPCW
(12;13).
A further potential issue with the Two-Stage method arises
around something called “re-censoring.” It is not discussed
here, due to its complexity, but it is discussed at length else-
where (2;17), and is summarized in the Supplementary Mate-
rial for this study. Importantly, the Two-Stage method can be
applied with or without re-censoring and either approach could
be prone to bias, depending upon the characteristics of the trial
and the treatment in question.
Rank Preserving Structural Failure Time Models (RPSFTM)
Like the Two-Stage method, the RPSFTM estimates survival
times that would have been observed had treatment switching
not occurred (18). The method involves three steps.
(1) First, for each patient, survival is split into two segments: time spent “on”
the experimental treatment (referred to as TOni ), and time spent “off”
the experimental treatment (referred to as TO f fi ), defined according to
treatment initiation and discontinuation times for each patient. In Sup-
plementary Figure 3a, this is illustrated for the fictitious RCT previously
introduced.
(2) The second step is reliant upon two key assumptions. It is assumed that if
no patients in either trial group had received the experimental treatment,
the average survival time in the two groups would have been equal be-
cause the two groups were created through randomization. It is further
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assumed that all patients, whether in the control or experimental group,
receive the same degree of benefit (treatment effect, or what is referred to
as e−ψ0 in the formula presented in Supplementary Figure 3b) from their
time on experimental treatment, known as the “common treatment effect”
assumption. Survival is, therefore, a simple function of time on and off
the treatment and the treatment effect (Supplementary Figure 3b).
Given these assumptions, a process called g-estimation is used to identify
the treatment effect. G-estimation essentially amounts to a grid search of
possible values for the treatment effect. Using the formula presented in
Supplementary Figure 3b, for each patient the inverse of the treatment ef-
fect (i.e., eψ0 ) is applied as a factor to the time spent on treatment, to nul-
lify the effect of having received the treatment, hence providing untreated
survival times (referred to as Ui in Supplementary Figure 3b). Once this
has been done for all patients, untreated survival times are compared be-
tween randomized groups; the “true” value of the treatment effect is the
one that results in equal untreated survival times between the randomized
groups.
(3) Once the “true” value of the treatment effect has been identified, adjusted
survival times can be calculated for the control group and compared with
the observed experimental group survival times to obtain an estimate of
the treatment effect adjusted for treatment switching (Supplementary Fig-
ure 3c).
The assumption that randomization has “worked” should
not be problematic in an RCT, and is also required by standard
ITT analyses. The common treatment effect assumption may
be more problematic, if the capacity to benefit from a treatment
is dictated by when it is received. In oncology trials, treatment
switching often occurs after some defined point of disease pro-
gression, and it may not be plausible to assume that switchers
will attain the same benefit from treatment (relative to the time
it is taken for) as those who received the treatment immediately
upon randomization. More complex versions of the RPSFTM,
which allow the common treatment effect assumption to be re-
laxed, have proven unsuccessful (17;19;20).
The structure of the RPSFTM model suggests that patients
must be either “on” or “off” treatment, if the control treatment
is active this may be problematic because it may be possible to
be on treatment x, on treatment y, or off treatment. The RPS-
FTM can still be applied in these circumstances, but requires
additional assumptions (2).
Simulations have shown that the RPSFTM performs ex-
tremely well when the common treatment effect assumption
holds (11–13). Also, RPSFTMs are less sensitive to issues aris-
ing from small patient numbers than the Two-Stage adjustment
and IPCW methods (12;13). However, problems can occur and
the g-estimation procedure may not work well with very small
patient and event numbers. Like the Two-Stage method de-
scribed in the previous section, the RPSFTM can be applied
with or without re-censoring (see the Supplementary Materials
for information on re-censoring).
THE VIEW OF DECISION MAKERS
While it has been reported that statistical approaches to adjust
for treatment switching in RCTs can provide reliable estimates
of causal treatment effects in a range of scenarios (2;11–13),
it was clear from discussions at the Workshop that the confi-
dence placed in these adjustment analyses differs substantially
between stakeholders. It appears that regulators are unlikely to
consider adjustment analyses sufficiently convincing on their
own for licensing purposes except in particular situations such
as when trials have a low degree of switching and/or where
there is substantial supportive evidence from other sources.
While some payers have used adjustment analyses to inform
recent decisions, many have not and all appear to have reserva-
tions. Some take these as grounds for ignoring adjustment anal-
yses entirely, either considering only ITT analyses (despite their
known inadequacies) or ignoring the trials entirely. Others at-
tempt to factor adjustment analyses into their wider appraisal of
evidence. Issues around the use of adjustment analyses appear
to fall into two broad categories: concerns over methodological
assumptions and confidence intervals, and issues around how
best to use adjustment analyses alongside other relevant infor-
mation in the decision-making process.
Concerns over Methodological Assumptions and Confidence Intervals
Each of the adjustment methods makes important assumptions.
While some of these may appear to lack face-validity in some
cases, analyses can be undertaken to provide information on
their validity for specific situations. Stakeholders at the Work-
shop agreed that if adjustment methods were used, the follow-
ing types of analyses should be undertaken to establish the ra-
tionale for each method on a case-by-case basis.
Investigation of the “No Unmeasured Confounders” Assumption. The assumption
of “no unmeasured confounders” is pivotal for the MSM/IPCW
and Two-Stage adjustment methods. It is impossible to test this
assumption fully, but information can be obtained from other
trials in similar disease areas to determine whether any likely
prognostic characteristics were not measured in the pivotal trial.
Clinical expert opinion could also be sought on its plausibility
(2). Discussion at the Workshop suggested that prognostic co-
variates (both for survival and for switching) should be iden-
tified as far as possible during trial planning, and data should
be collected on these during the trial. Importantly, this data col-
lection should be continued beyond disease progression to en-
hance the likelihood that the full range of adjustment methods
can subsequently be applied.
Investigation of the Likely Bias Associated with Two-Stage Adjustment. If there is a
significant time-lag between the secondary baseline and the
treatment switch, the Two-Stage adjustment method becomes
prone to bias (2). Hence, analyses of time-to-switch should be
undertaken, to provide information on the scope for bias. For
instance, if an analysis of the time from secondary baseline
to time of switch demonstrates that all switchers began to re-
ceive the experimental treatment very soon after disease pro-
gression (in a matter of days), the scope for time-dependent
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confounding is minimal. In contrast, if patients switched
months or years after the secondary baseline the scope for time-
dependent confounding is much higher.
Investigation of the “Common Treatment Effect” Assumption. The “common treat-
ment effect” assumption is pivotal for RPSFTM. It is impossi-
ble to test this assumption fully, but attempts should be made to
assess its validity. This could be achieved, for instance, by using
the Two-Stage adjustment method to derive and compare treat-
ment effect estimates for switchers and for patients randomized
to the experimental group. Also, clinical expert opinion could
be sought to determine the biological plausibility of a common
treatment effect (2). If the common treatment effect assump-
tion is deemed implausible, the extent to which the treatment
effect differs between groups could be investigated to provide
information on the potential size of the bias associated with a
violation of this assumption.
Investigation of Other Factors. Several other factors should be investi-
gated:
(1) Adjustment methods (particularly the MSM/IPCW) become prone to
higher levels of error when the switching proportion is very high and/or
the sample size in strata/cells defined by combinations of covariates used
within the MSM is small and/or the number of events observed in these
strata/cells is low (2;12;13;21). Details on each of these should be pre-
sented to allow reviewers to assess the scope for bias.
(2) It is possible to apply the RPSFTM under the assumption of a treatment
effect that either stops or continues at the point of treatment discontinua-
tion, and to apply the RPSFTM and Two-Stage adjustment methods with
or without re-censoring (there are circumstances where re-censoring it-
self can lead to bias) (2;17). The appropriateness of each of these options
should be investigated by studying the treatment effect over time, and the
impact of re-censoring.
(3) The most common perceived need for adjustment is to address switch-
ing from the control group onto the experimental treatment. However, if
other switches occur, in either group, consideration should be given to
adjusting for these: if we adjust for switching in the control group, it may
be argued that we should also adjust for switches from the experimental
group onto other investigational or nonstandard treatments.
Confidence Intervals. In addition to the assumptions involved in an
adjustment analysis, there may be concerns about the confi-
dence intervals of the estimates they generate. For the RPS-
FTM, it should be recognized that often confidence intervals
will widen, compared with the ITT analysis, primarily as a re-
sult of the method design: If the ITT analysis does not provide
a statistically significant result, the equivalent RPSFTM analy-
sis also will not, because typically the ITT analysis p value is
retained. In contrast, an MSM/IPCW may result in narrower
confidence intervals, though this is dependent upon the co-
variate data available. For regulators and HTA agencies, this
uncertainty may be important. For those only willing to con-
sider statistically significant results, the standard application of
the RPSFTM may be of limited utility, particularly in circum-
stances where the ITT analysis does not produce a statistically
significant result.
Using Adjustment Analyses and Other Relevant Information in Decisions
Although decision makers appear to be reluctant to place re-
liance on methods that they and/or their stakeholders do not
fully understand, they appear to accept that ignoring the likely
effects of switching in trials may lead to underestimation of
the extent of benefits and possible harmful effects and, in some
cases, decisions that deny patients access to effective products.
There is, therefore, an interest in using adjustment analyses as
an indicator of the likely extent of confounding that switching
gives rise to, and to at least consider such analyses in an over-
all judgement of the likely comparative effectiveness and cost-
effectiveness of a new treatment. Those making such judge-
ments may also find it helpful to see data from sources outside
the pivotal trial.
Sources of relevant data from outside the main trial include
registry data (retrospective or prospective alongside the trial) or
data from other trials that may inform estimates of long-term
survival unaffected by switching (2;22). External data from rel-
evant RCTs unaffected by treatment switching that included the
same endpoints as the trial under investigation are likely to be
particularly useful.
It was recognized in discussions that using external or ob-
servational data is likely to give rise to methodological issues,
such as population and protocol differences and the age of the
data. But such analyses may still represent useful supporting
evidence, particularly if patient-level data can be obtained such
that adjustments can be made for differences in patient charac-
teristics. Again, it was clear from discussions at the Workshop
that the acceptability of combining data from multiple sources
varied between stakeholders, reflecting concerns regarding va-
lidity and relevance.
PROPOSALS FOR GOOD PRACTICE IN RELATION TO TREATMENT
SWITCHING
Several strong messages around the analysis of trials affected
by treatment switching emerged from the Workshop:
(1) In the presence of treatment switching that is deemed to materially af-
fect the results of a trial, a standard ITT analysis may usefully be sup-
plemented with analyses that attempt to adjust for switching and which
may help to address the particular decision problems faced by different
stakeholders.
(2) Where adjustment methods are used, trial characteristics and the treat-
ment switching mechanism should be considered alongside the pivotal
assumptions associated with each of the statistical adjustment methods
to identify which of the analyses are likely to provide the least amount of
bias.
(3) The sensitivity of results should be tested through application of all meth-
ods deemed to be potentially appropriate: If a range of methods are shown
to be potentially appropriate for a particular case, and each provides sim-
ilar estimates of the treatment effect, decision makers may have more
confidence in the results.
(4) Appropriate use of external data may be explored, to provide further sup-
portive evidence.
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FURTHER RESEARCH
Important limitations with adjustment methods remain, and
various reservations regarding their use for decision-making
purposes are legitimate. Barriers to the use of adjustment meth-
ods largely relate to a mis-trust of methodological assumptions
and an inability by some fully to understand the theoretical ba-
sis for the methods (and, therefore, to appraise their strengths
and weaknesses). Further exploration of the specific reserva-
tions held by different decision makers may provide the cata-
lyst for a provision of education to address some of these, while
also highlighting areas where further methodological research
is needed, conducted in the light of real world decision making
contexts and constraints.
Discussions with international stakeholders in follow-up to
the Adelaide meeting are ongoing, which will hopefully allow
research areas to be identified in a timely manner. Areas of par-
ticular value are likely to address formal methods for assess-
ing the validity of the key assumptions made by the adjustment
methods, and methods for integrating evidence from external
trials or observational studies to estimate what survival would
have been in the absence of switching. Further research would
permit more detailed guidance on how to identify an appropri-
ate adjustment method for a specific trial, and how the design
of trials and wider clinical development programs might better
be adapted to support the use of adjustment methods.
CONCLUSIONS
There is a need for decision makers to openly engage with the
use of adjustment methods in the presence of treatment switch-
ing in RCTs. A standard ITT analysis is highly likely to pro-
duce a biased estimate of the comparative treatment effect in
the presence of switching (typically underestimating benefits
and possible harms), and although adjustment methods are not
perfect, evidence suggests that they will often provide an esti-
mate of the treatment effect that is closer to the truth (2;11–13).
It is important that trials provide information that addresses the
needs of decision makers, otherwise their ethical justification is
questionable. It is hoped that this study and its companion (5)
will help trial sponsors plan, manage and analyze trials where
treatment switching can be expected so as to provide better in-
formation for decision makers.
It can also be argued that there is an ethical obligation for
decision makers to make appropriate use of information from
trials for which patients have volunteered in the belief that they
will be contributing to better decisions, taking due account of
the possible shortcomings of such information. It is hoped that
this study, and further research on this topic, will help deci-
sion makers understand the value and limitations of adjustment
methods and how these can be used to analyze trials that are
relevant for decisions but biased by treatment switching. It is
further hoped that this will lead to increased appropriate use of
these methods and to better informed decisions.
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